Mar 4 |
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
|
Jan 24 |
Bioventus: Bullish On Path To Profitability
|
Jan 18 |
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
|
Jan 12 |
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
|
Dec 19 |
Bioventus appoints Robert Claypoole as president and CEO
|
Dec 19 |
Bioventus Names Robert Claypoole as President and Chief Executive Officer
|
Dec 6 |
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
|
Nov 27 |
Smith & Nephew inks $180M CartiHeal buyout, capitalizing on Bioventus turmoil to land knee implant
|
Nov 12 |
Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript
|
Nov 12 |
Bioventus Inc. (BVS) Q3 2023 Earnings Call Transcript
|